COVID-19 and the Pandemic-Related Aspects in Pediatric Demyelinating Disorders

IF 2.4 4区医学 Q2 CLINICAL NEUROLOGY

Seminars in Pediatric Neurology Pub Date : 2023-07-01 DOI:10.1016/j.spen.2023.101055

Grace Gombolay, Jamika Hallman-Cooper

{"title":"COVID-19 and the Pandemic-Related Aspects in Pediatric Demyelinating Disorders","authors":"Grace Gombolay, Jamika Hallman-Cooper","doi":"10.1016/j.spen.2023.101055","DOIUrl":null,"url":null,"abstract":"<div><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as Coronavirus-19 (COVID-19) infection, has been associated with several neurological symptoms, including acute demyelinating syndromes (ADS). There is a growing body of literature discussing COVID-19 and demyelinating conditions in adults; however, there is less published about COVID-19 demyelinating conditions in the pediatric population. This review aims to discuss the impact of COVID-19 in pediatric patients with central nervous system ADS (cADS) and chronic demyelinating conditions. We reviewed PubMed, Google Scholar, and Medline for articles published between December 1, 2019 and October 25, 2022 related to COVID-19 and pediatric demyelinating conditions. Of 56 articles reviewed, 20 cases of initial presentation of ADS associated with COVID-19 were described. The most commonly described cADS associated with COVID-19 infection in children was Acute Disseminated Encephalomyelitis followed by Transverse Myelitis. Cases of Myelin Oligodendrocyte Glycoprotein Antibody Disease, Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis are also described. The risk of severe COVID-19 in pediatric patients with demyelinating conditions appears low, including in patients on disease modifying therapies, but studies are limited. The pandemic did affect disease modifying therapies in ADS, whether related to changes in prescriber practice or access to medications. COVID-19 is associated with ADS in children and the COVID-19 pandemic has impacted pediatric patients with demyelinating conditions in various ways.</p></div>","PeriodicalId":49284,"journal":{"name":"Seminars in Pediatric Neurology","volume":"46 ","pages":"Article 101055"},"PeriodicalIF":2.4000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169322/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Pediatric Neurology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1071909123000244","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as Coronavirus-19 (COVID-19) infection, has been associated with several neurological symptoms, including acute demyelinating syndromes (ADS). There is a growing body of literature discussing COVID-19 and demyelinating conditions in adults; however, there is less published about COVID-19 demyelinating conditions in the pediatric population. This review aims to discuss the impact of COVID-19 in pediatric patients with central nervous system ADS (cADS) and chronic demyelinating conditions. We reviewed PubMed, Google Scholar, and Medline for articles published between December 1, 2019 and October 25, 2022 related to COVID-19 and pediatric demyelinating conditions. Of 56 articles reviewed, 20 cases of initial presentation of ADS associated with COVID-19 were described. The most commonly described cADS associated with COVID-19 infection in children was Acute Disseminated Encephalomyelitis followed by Transverse Myelitis. Cases of Myelin Oligodendrocyte Glycoprotein Antibody Disease, Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis are also described. The risk of severe COVID-19 in pediatric patients with demyelinating conditions appears low, including in patients on disease modifying therapies, but studies are limited. The pandemic did affect disease modifying therapies in ADS, whether related to changes in prescriber practice or access to medications. COVID-19 is associated with ADS in children and the COVID-19 pandemic has impacted pediatric patients with demyelinating conditions in various ways.

查看原文本刊更多论文

新冠肺炎与小儿脱髓鞘疾病的流行相关因素

严重急性呼吸综合征冠状病毒2（SARS-CoV-2），也称为冠状病毒-19（新冠肺炎）感染，与包括急性脱髓鞘综合征（ADS）在内的几种神经系统症状有关。越来越多的文献讨论新冠肺炎和成人脱髓鞘情况；然而，关于儿科人群中新冠肺炎脱髓鞘情况的报道较少。本综述旨在讨论新冠肺炎对中枢神经系统ADS（cADS）和慢性脱髓鞘疾病儿童患者的影响。我们回顾了PubMed、Google Scholar和Medline在2019年12月1日至2022年10月25日期间发表的与新冠肺炎和儿科脱髓鞘条件相关的文章。在回顾的56篇文章中，描述了20例首次出现与新冠肺炎相关的ADS病例。与儿童新冠肺炎感染相关的最常见的cADS是急性弥漫性脑脊髓炎，其次是横贯性脊髓炎。还描述了髓鞘少突胶质细胞糖蛋白抗体疾病、神经脊髓炎视谱障碍和多发性硬化症的病例。患有脱髓鞘疾病的儿科患者患严重新冠肺炎的风险似乎很低，包括接受疾病改良疗法的患者，但研究有限。疫情确实影响了ADS的疾病改良疗法，无论是与处方医生实践的变化还是药物的获取有关。新冠肺炎与儿童ADS相关，新冠肺炎大流行以各种方式影响了患有脱髓鞘疾病的儿科患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in Pediatric Neurology CLINICAL NEUROLOGY-PEDIATRICS

CiteScore

4.80

自引率

0.00%

发文量

审稿时长

84 days

期刊介绍： Seminars in Pediatric Neurology is a topical journal that focuses on subjects of current importance in the field of pediatric neurology. The journal is devoted to making the status of such topics and the results of new investigations readily available to the practicing physician. Seminars in Pediatric Neurology is of special interest to pediatric neurologists, pediatric neuropathologists, behavioral pediatricians, and neurologists who treat all ages.